**SUPPLEMENTARY INFORMATIONS**

# Multifunctional platinum@BSA-rapamycin nanocarriers for the combinatorial therapy of Cerebral Cavernous Malformation

Elisa De Luca[a], Deborah Pedone[a,b], Mauro Moglianetti[a], Daniele Pulcini[a], Andrea Perrelli[c,d], Saverio Francesco Retta[c,d]* and Pier Paolo Pompa[a,e,]*

[a] Istituto Italiano di Tecnologia, *Nanobiointeractions&Nanodiagnostics,* Center for Biomolecular Nanotechnologies, Via Barsanti 14, 73010, Arnesano (Lecce) Italy.

[b] University of Salento, Department of Engineering for Innovation, Via per Monteroni, 73100, Lecce, Italy

[c] University of Torino, Department of Clinical and Biological Sciences, 10043, Orbassano (Torino), Italy.

[d] CCM Italia research network (www.ccmitalia.unito.it)

[e] Istituto Italiano di Tecnologia, *Nanobiointeractions&Nanodiagnostics,* Via Morego 30, 16163, Genova, Italy

* Corresponding authors: pierpaolo.pompa@iit.it; francesco.retta@unito.it

| | Intensity (nm) | Volume (nm) |
|---|---|---|
| Pt5 | 13±5 | 9±3 |
| Pt5@Rapa | 45±18 | 30±11 |

**Table S1**. Hydrodynamic diameter calculated for intensity distribution and volume distribution, measured by DLS, of Pt5 and Pt5@Rapa NPs.




**Figure S1.** Treatment of KRIT1-KO MEFs with 500 nM rapamycin restores p62 expression to the levels of wild-type MEFs.




**Figure S2.** Cytocompatibility of Pt5 NPs on HUVECs.